What's Inside


Peds ID Home
Minnesota Medical Foundation Make a Gift
Vikings Children's Fund
Children's Cancer Research Fund
OPs Administrative Center

 

 
  Home > Faculty > Mark R. Schleiss, M.D.
 

Mark R. Schleiss, M.D.

Dr. Mark Schleiss

Professor, Pediatrics
Director, Division of Pediatric Infectious Diseases and Immunology
Associate Chair for Research, Department of Pediatrics
Center for Infectious Diseases and Microbiology Translational Research (http://www.cidmtr.umn.edu/)
2001 6th Street SE
3-214 MTRF
Minneapolis, MN  55455
Phone: (612) 626-9913
Fax: (612) 624-8927
schleiss@umn.edu

Mark R. Schleiss, M.D. is a Professor of Pediatrics in the University of Minnesota Medical School. Dr. Schleiss is the Director, Division of Infectious Diseases and Immunology, and Associate Chair for Research in the Department of Pediatrics.

Dr. Schleiss received his M.D. degree from the Oregon Health and Sciences University, Portland, Oregon. He completed his residency at Doernbecher Children’s Hospital, Oregon Health and Sciences University, Portland, Oregon and his Pediatric Infectious Diseases fellowship at Children’s Hospital Medical Center, University of Washington, Seattle, Washington. He also completed a fellowship in Molecular Medicine studying cytomegalovirus molecular genetics at the Fred Hutchinson Cancer Research Center, Seattle, Washington. His laboratory at the UMN Center for Infectious Diseases and Microbiology Translational Research is described at this link: http://www.cidmtr.umn.edu/investigators/schleiss/home.html. His research on CMV vaccines is described at this link: http://www.ahc.umn.edu/research/cytomegalovirus/index.htm

Honors

1979Associate Member, Sigma Xi Research Honor Society, Stanford, California
1995Distinguished Service Award, Association for Retarded Citizens (ARC) Hamilton County, Ohio
1999Mead-Johnson Teaching Award
2000-2003Society for Pediatric Research, Council Member (www.aps-spr.org)
2001-2009Member, Federation of Pediatric Organizations (FOPO) and Pediatric Education Steering Committee (PESC), www.fopo.org
2003, 2004Golden Spoon House Staff Teaching Award, Cincinnati Children's Hospital
2005-2009Society for Pediatric Research, Secretary - Treasurer (www.aps-spr.org)
2009-presentBoard Member, Brendan M. McGinnis Congenital CMV Foundation (www.cmvfoundation.org)
2008-2010"Best Doctors in America" Member
2009-presentMember, Immunity and Host Defense (IHD) Study Section, National Institutes of Health

Selected Recent Publications  

Intravaginal cytomegalovirus (CMV) challenge elicits maternal viremia and results in congenital transmission in a guinea pig model. Olejniczak MJ, Choi KY, McVoy MA, Cui X, Schleiss MR. Virol J. 2011, 8:89. PMID: 21371319.

Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission? Schleiss MR. J Infect Dis. 2011, 203(11):1513-6. PMID: 21592979.

A cytomegalovirus vaccine tames the troll of transplantation. Schleiss MR. Lancet. 2011, 377:1216-8. PMID: 21481691.

Cytomegalovirus-induced sensorineural hearing loss with persistent cochlear inflammation in neonatal mice. Schachtele SJ, Mutnal MB, Schleiss MR, Lokensgard JR. J Neurovirol. 2011, 17(3):201-11. PMID: 21416394.

Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV. McGregor A, Choi KY, Schleiss MR. Virology. 2011, 410(1):76-87. PMID: 21094510.

Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines. Schleiss MR. J Clin Invest. 2010, 120(12):4192-7. PMID: 21099107.

Update on the current status of cytomegalovirus vaccines. Sung H, Schleiss MR. Expert Rev Vaccines. 2010, 9(11):1303-14. PMID: 21087108.

Prevention of maternal cytomegalovirus infection: current status and future prospects. Nyholm JL, Schleiss MR. Int J Womens Health. 2010, 2:23-35. PMID: 21072294.

Screening newborns for congenital cytomegalovirus infection. Dollard SC, Schleiss MR. JAMA. 2010, 304(4):407-8. PMID: 20664037.

Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus. Dollard SC, Schleiss MR, Grosse SD. J Inherit Metab Dis. 2010, 33:S249-54. PMID: 20532822.

Child health research funding and policy: imperatives and investments for a healthier world. Hay WW Jr, Gitterman DP, Williams DA, Dover GJ, Sectish TC, Schleiss MR. Pediatrics. 2010, 125(6):1259-65.

A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Crumpler MM, Choi KY, McVoy MA, Schleiss MR. Vaccine. 2009, 27(31):4209-18. PMID: 19389443.

The impact of genome length on replication and genome stability of the herpesvirus guinea pig cytomegalovirus. Cui X, McGregor A, Schleiss MR, McVoy MA. Virology. 2009, 386(1):132-8. PMID: 19174305.

Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Cheeran MC, Lokensgard JR, Schleiss MR. Clin Microbiol Rev. 2009, 22(1):99-126. PMID: 19136436.

VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Schleiss MR. Curr Opin Mol Ther. 2009, 11:572-8. PMID: 19806506. 

 

 

 

Feedback | Notice of Privacy Practices